An almost universal side effect of long-term therapy with procainamide is the appearance of serum autoantibodies and less frequently a syndrome resembling lupus erythematosus. Previous studies demonstrated that procainamide-hydroxylamine (PAHA), a metabolite generated by hepatic mixed function oxidases, was highly toxic to dividing cells, but evidence that PAHA could be formed in the circulation was lacking. This study examines the capacity of neutrophils to metabolize procainamide to reactive forms. Neutrophils activated with opsonized zymosan were cytotoxic only if procainamide was present, whereas N-acetyl procainamide, which does not induce autoimmunity, was inert in this bioassay. PAHA was detected by HPLC in the extracellular medium if ascorbic acid was present. Generation of PAHA and cytotoxic procainamide metabolites was inhibited by NaN3 and catalase but not by superoxide dismutase, indicating that H202 and myeloperoxidase were involved. Nonactivated neutrophils and neutrophils from patients with chronic granulomatous disease did not generate cytotoxic PAHA, demonstrating that H202 was derived from the respiratory burst accompanying neutrophil activation. These conclusions were supported by results of a cell-free system in which neutrophils were replaced by myeloperoxidase and H202 or an H202 generating system. These studies demonstrate the capacity of neutrophils to mediate metabolism of procainamide and establish the role of myeloperoxidase released during degranulation and H202 derived from the respiratory burst in the direct cooxidation of procainamide to PAHA. The profound biologic activity of this metabolite and its possible generation within lymphoid compartments implicate this process in the induction of autoimmunity by procainamide.
Introduction
Antinuclear antibodies commonly arise during long-term treatment with procainamide, and 15-20% of these patients develop a lupus-like illness (1, 2) . The mechanism for procainamide-induced autoimmunity has not been established, but various hypotheses have been explored including allergiclike hypersensitivity reactions, polyclonal activation, and perturbation of lymphocyte recognition processes.
Procainamide contains an aromatic amino group that is acetylated in vivo by hepatic acetyl transferases. The genetically determined slow acetylator phenotype is associated with more rapid onset of autoantibodies and symptomatic drug-induced lupus compared to rapid acetylators (3) , and the N-acetylated derivative of procainamide fails to induce autoantibodies and symptoms of lupus (4, 5) . These observations were interpreted to suggest that the free amino group on procainamide participates directly in the induction of autoimmunity and stimulated numerous attempts to demonstrate in vitro effects of procainamide on lymphocyte function and/or affinity for macromolecules. Conflicting results (6-11) and even immunosuppressive effects (6, 9, 12) have been reported in studies using pharmacologically realistic procainamide concentrations, raising doubts about a direct role for procainamide in autoimmunity induction.
An alternative explanation for the inability of N-acetyl procainamide to induce autoimmunity is that metabolism of procainamide near the aromatic amine moiety generates the active, autoimmunity inducing compound, and acetylation blocks this transformation. We recently demonstrated that one procainamide analogue, procainamide-hydroxylamine (PAHA),' is highly cytotoxic to many cell types in vitro, killing rapidly dividing cells including activated lymphocytes at concentrations well within the in vivo therapeutic concentration of procainamide (13) . However, previous studies showed procainamide metabolism to the hydroxylamine only by the microsomal fraction from rat and human liver homogenates containing an NADPH generating system (14, 15) . Since PAHA is highly reactive, rapidly binding to microsomal proteins (16) and losing its cytotoxic potency in high serum concentrations (13) , the potential for liver generated PAHA to react with extrahepatic lymphoid tissue appeared unlikely. Presence of PAHA within a lymphoid compartment would seem to be a prerequisite to implicate it in the initiation or maintenance of immune dysfunction leading to autoimmunity.
Our preliminary results suggested that peripheral blood neutrophils may mediate oxidation of procainamide to PAHA (17) , and this has been confirmed (18) . By application of a bioassay for cytotoxic procainamide metabolites as well as direct chemical analyses, the current study demonstrates the capacity of activated neutrophils to metabolize procainamide to the cytotoxic hydroxylamine. These results provide the precedent and delineate a mechanism for an immunologically rele-vant transformation of procainamide to a potentially pathogenic form.
Methods
Human donors. Normal neutrophils were obtained from healthy donors who avoided anti-inflammatory drugs including aspirin for one week before blood donation. Neutrophils with abnormal respiratory burst capacities were obtained from patients with chronic granulomatous disease (CGD). One patient was a 19-yr-old male with the classic, X-linked/cytochrome b558-negative form of CGD (19) . Neutrophils from this patient contained no detectable cytochrome b558 by spectrophotometric (19) or Western blot analyses (20) , and showed no respiratory burst activity when stimulated with either phorbol 12-myristate 13-acetate (PMA) or opsonized zymosan (see Results). Another patient was a 35-yr-old female with the rare autosomal recessive/cytochrome b55g-negative form of CGD (20) (21) (22) (23) . Her cells showed a negligible respiratory burst in response to PMA (see Results).
Preparation ofneutrophils. Neutrophils were isolated from blood anticoagulated with 0.057 M acidic citrate buffer containing 0.037 M dextrose based on methodologies previously described (19, 24) . Briefly, erythrocytes were removed by 1 g sedimentation through 2% dextran and by rapid lysis ofthe leukocyte containing supernatant with ice cold water, twice. Platelets were removed by repeated washing of pelleted leukocytes in PBS (0.01 M phosphate buffer, 0.14 M NaCi, pH 7.4 in deionized water) at 40C, and neutrophils were separated from mononuclear cells by sedimentation through a Ficoll-Hypaque step gradient. The neutrophil pellet was washed twice in PBS, 40C. Viability by trypan blue dye exclusion and purity were routinely > 97%. Cell numbers were determined by hemocytometer count, and the preparation was stored on ice for use within a few hours.
Neutrophil function assays. Respiratory burst was measured by generation ofsuperoxide anion (O°) based on Johnston and Lehmeyer (25) , and Van Epps et al. (26) . Neutrophils were suspended in Dulbecco's PBS (ICN Radiochemicals, Irvine, CA) containing 1 mg/ml glucose, and 0.08 mM (1.0 mg/ml) cytochrome c (Sigma Chemical Co., St. Louis, MO, type III). Boiled zymosan (type A, Sigma Chemical Co.) was washed in PBS and incubated with human serum (fresh or stored at -70°C) for 0.5 h, 37°C at a ratio of 80 mg zymosan/10 ml serum. The opsonized zymosan was washed twice in PBS by centrifugation at 1,500 rpm, 5 min, and suspended in PBS at 25 mg/ml. Since these preparations were occasionally toxic to. the target cells, they were routinely treated with the protease inhibitor 6-amidino-2-naphthyl4-guanodinobenzoate dihydrochloride (27) at 25 ,g/ml for 10 min, at 25°C. The opsonized zymosan was again washed twice in PBS and used the same day. PMA (Sigma) was dissolved at 10 Mg/ml in dimethylsulfoxide and stored at -20°C. O2 was determined by cytochrome c reduction measured at 550 nm either 7-10 min after addition of activator or by using continuous kinetics measurements monitored in a spectrophotometer (Kontron, Zurich, Switzerland). Reactions were carried out in a final volume of 1.1 ml at 37°C using reactant concentrations as shown in Results. Supplements to the assay mixture were added before addition of activator.
Myeloperoxidase activity was measured by a modification of the procedure of Bretz and Baggiolini (28) . Neutrophils were suspended in Dulbecco's PBS at 6 X 106/ml containing 1 mg/ml glucose, I mg/ml human serum albumin. After treatment with activator for 15 min at 37°C, 20 Al of serial twofold dilutions of the neutrophil free supernatant were added in replicates to wells ofmicrotiter plates. The reaction was initiated by the addition of 200 ;1 of o-dianisidine at 0.1 mg/ml in citrate buffer, pH 5.5, 0.05% Triton X-100, 0.08 mM H202. A standard curve was generated using horseradish peroxidase (Sigma) at 0.005-0.02 U/ml. The Qptical density at 450 nm was determined at 15-30 min using an MR600 ELISA reader (Dynatech Laboratories, Alexandria, VA), and equivalent units of peroxidase activity were determined from the linear region ofthe standard curve. (13) . Nitrosoprocainamide was a gift from Dr. Evelyn Hess, University of Cincinnati Medical Center. NAPA was used as an internal standard in every analysis to monitor recoveries. Peaks were quantified by area integration and converted to nanomoles of analogue based on similar analyses using known concentrations of the respective analogue. In some cases samples were pretreated with 0.1 N NaOH for 5 min followed by neutralization with 0.1 N acetic acid to oxidize PAHA before analysis.
Cytotoxicity assay. Detection of cytotoxic metabolites of procainamide was based on previous studies in which cell lines exposed to procainamide analogues were assessed for viability by [3H]thymidine incorporation into DNA. Viability as measured by DNA synthesis correlated with trypan blue dye exclusion and tetrazolium dye reduction (13) . The cytotoxicity assay was based on the capacity ofactivated neutrophils to kill GM4672B cells (Human Genetic Mutant Cell Repository Institute for Medical Research, Camden, NJ) when procainamide was present. In the standard assay, 0.5 ml log phase, washed GM4672B cells in the presence or absence of procainamide (E. R. Squibb & Sons, Princeton, NJ) were mixed with 0.2 ml of various concentrations of neutrophils in 12 X 75 mm polypropylene tubes followed by addition of 30 M1 of opsonized zymosan at 25 mg/ml.
Opsonized zymosan was sterilized by 3,200 R y-irradiation. The final concentration of reactants was generally 1.5 X 105 GM4672B cells/ml, 0.3-1.2 X 106 neutrophils/ml, 50MAM procainamide, 7.5 MCi/ml [3H]-thymidine (ICN Radiochemicals) and 1.0 mg/ml opsonized zymosan all in DME containing high glucose concentration and 10% fetal bovine serum (Hyclone Labs, Logan, UT). Tubes were loosely capped and placed in a 370C incubator equilibrated with 10% CO2 and harvested in 0. 1-ml quadruplicate aliquots the following day as previously described (13) .
In some experiments a two-stage assay was performed in which
[3H]thymidine was absent during a 1-h first'stage that contained all the other reactants followed by centrifugation and replacement of the medium with complete medium containing [3H1thymidine. The role of NaCG was examined in this two-stage assay by replacing the standard medium in the first stage with a chloride-free medium, consisting of 0.25 M sucrose, 7.5 mM glucose, 0.01 M sodium phosphate, 0.5 mM calcium lactate, 0.5 mM magnesium sulfate and 10% fetal bovine serum exhaustively dialyzed against chloride-free medium using a 2,000 D cutoff membrane. Opsonized zymosan was washed in chloride-free medium before use. Cell-free oxidation ofprocainamide. The capacity of myeloperoxidase (MPO) to mediate oxidation of procainamide was evaluated by HPLC. MPO was'isolated from normal neutrophils disrupted by nitrogen cavitation as previously described (19) . Briefly, azurophil granules were banded by discontinuous Percoll density gradient ultracentrifugation' and washed free of Percoll by centrifugation in an SW41Ti rotor at 37,000 rpm, 90 min, 50C. Granules were disrupted by sonication and stored in 0.34 M sucrose at -70'C. MPO activity was determined exactly as performed on neutrophil supernatants. Procainamide oxidation experiments were initially optimized with respect to MPO and substrate concentrations and incubation duration. Reactions were generally performed in 12 X 75 mm polypropylene tubes in a final volume of 0.5 ml. The standard conditions consisted of procainamide and NAPA at 30 and 7 jM, respectively, in Dulbecco's PBS followed by addition of MPO to a final concentration of 5 mU/ml. Ascorbic acid to I mM and hypoxanthine (HX) to 0.1 mM were added in some experiments. The reaction was initiated by addition of either H202 or xanthine oxidase (Sigma, grade III). After 30 min at 370C, the reaction was terminated by ultrafiltration onto dry ice and analyzed by HPLC as previously described. In some experiments Dulbecco's PBS was replaced with 0.01 MI phosphate buffer, pH 7.4 with or without 0.14 M NaCl.
Results
A human lymphoblastoid B-cell line, GM4672B, was used as the bioindicator for the presence ofcytotoxic products by measurement of 24 icity response at 0.3 X 106 neutrophils/ml followed by a stoichiometric decrease with increasing neutrophil concentration, reaching negligible cytotoxicity at 4.8 X 106 neutrophils/ml.
As also shown in this figure, suppression of cytotoxicity was not due to decrease in the amount of PAHA generated since PAHA production showed a linear increase with neutrophil concentration up to 2. The curious inhibition of procainamide cytotoxicity when neutrophil concentration exceeded -1 X 106/ml was consistently observed with most donors although the exact cell density for maximum cytotoxicity varied from donor to donor. In contrast to neutrophil mediated procainamide cytotoxicity, PAHA production increased with increasing neutrophil concentration as shown in Fig. 3 . This suggested the possibility that a factor was released from neutrophils which protected target cells from the toxic action of PAHA. Such a phenomenon was supported by the experiment shown in Table I . When supernatant from increasing concentrations of activated neutrophils was added to viable neutrophils, procainamide cytotoxicity was concomitantly decreased. Inhibition of neutrophil mediated procainamide cytotoxicity was not paralleled by a decrease in PAHA accumulation which remained unaffected by addition of neutrophil supernatant (Table I ). These results demonstrate the presence of an inhibitor of the cytotoxic procainamide metabolites, released in a dose-dependent fashion from activated neutrophils.
Role ofneutrophil oxidative metabolism. The major events associated with neutrophil activation are a respiratory burst and lysosomal degranulation resulting in production of superoxide anion and release of myeloperoxidase into the extracellular environment. The role of these mediators in procainamide oxidation and cytotoxicity was explored by the use of competing enzymes and inhibitors of these processes. As shown in Table II superoxide dismutase (SOD) quantitatively eliminated°2 generated after activation of neutrophils with opsonized zymosan without inhibiting release of the azurophil granule enzymes MPO and beta glucuronidase. Hydrogen peroxide (H202), the product of SOD action on O-, can be hydrolyzed by addition of catalase; at a catalase concentration of PAHA production was measured under conditions similar to those used in Table II O- and therefore H202, the role of these potential reactants in procainamide oxidation can be determined. Two patients were studied. CGD1 was a male with the X-linked/cytochrome b558 negative form of CGD and had no capacity to generate O2 as shown in Table IV ; CGD2 was a female with autosomal recessive/cytochrome b558 negative disease and produced a small amount of O2 (1-2% of normal). The capacity of neutrophils from each of these patients to generate PAHA was greatly reduced when compared to normal controls tested on the same day (Table IV) . Neutrophils from both patients failed to mediate cytotoxic procainamide formation as shown in Fig. 4 . These results indicate that procainamide oxidation requires°2 released during the respira- Procainamide oxidation in a cellfree system. The previous results suggested that isolated MPO should be able to mediate the oxidation of procainamide to PAHA in the presence of H202. This was confirmed using either direct addition ofH202 or an H202 generating system, xanthine oxidase (XO) plus hypoxanthine (HX), as shown in Table V . Concentrations of . 0.1 mM H202 in the absence of MPO did not oxidize procainamide (data not shown). PAHA was detected after incubation of procainamide with MPO and 0.03 mM H202 if ascorbic acid was added to a final concentration of 1 mM; in the absence of ascorbic acid no PAHA was detected but larger amounts of nitro-PA and a peak eluting at 5 min appeared. This peak coelutes with the nitroso derivative of procainamide, which is derived from the spontaneous oxidation of PAHA in the absence ofascorbic acid (16). Similar results were obtained with HX and 5 mU/ml XO. This XO concentration generated 1.2 nmol O/min in the cytochrome c reduction assay, similar to the O2 producing capacity of 6 X 106 neutrophils/ml activated with opsonized zymosan (Table II) . Appearance of PAHA, nitro-PA or presumed nitroso-PA was prevented by omission of procainamide or MPO or by the use of boiled MPO or XO (data not shown). Although we could not test the cytotoxic properties ofthese mixtures due to toxicity of the reactants in the absence ofprocainamide, the HPLC analyses of this cell free system are compatible with results obtained using intact neutrophils demonstrating the key role of MPO in generation of cytotoxic procainamide.
Hypochlorite ion is not responsible for procainamide oxidation to the hydroxylamine. In the presence of chloride ions the primary product of MPO-mediated H202 hydrolysis is To directly test whether C1-may be involved in neutrophil-mediated oxidation of procainamide, we measured the generation of cytotoxic PAHA in the presence or absence of 0.14 M NaCl. Since the bioassay requires overnight incubation of the target cells in complete tissue culture medium, a two stage assay was performed in which the mixture of neutrophils and target cells in either complete medium or in chloride-free isotonic medium (see Methods) was resuspended in complete medium containing [3H]thymidine 1 h after activation with opsonized zymosan. In complete medium in the 2 stage assay, target cell killing due to the presence of procainamide in the activation step was 57%, 58%, and 37% at 0.3, 0.6, and 1.2 X 106 neutrophil/ml, respectively, compared to 57%, 43%, and 15% in the standard one stage assay performed in parallel. When the first stage was done in chloride-free medium, activated neutrophils were > 50% cytotoxic in the absence of procainamide, so the capacity of neutrophils to metabolize procainamide to a cytotoxic product could not be evaluated. However, by HPLC analysis 1.1 ,uM PAHA was detected in the chloride-free medium compared to 1.3 ,M PAHA in the standard chloride-containing medium, suggesting that C1-was not involved in oxidation of procainamide to PAHA by neutrophils. (G2 production in response to opsonized zymosan in chloride-free medium was 40% below normal.) However, since intracellular chloride cannot be removed, this experiment does not absolutely eliminate a role of OC1-in procainamide oxidation.
The capacity of MPO in the cell-free system to support procainamide oxidation to PAHA facilitated examination of the role of OC1-in this process. HPLC analysis of procainamide treated with MPO in the presence or absence of NaCl using xanthine oxidase as the H202 generating system is shown in Evidence for the linkage of procainamide oxidation with MPO action on H202 includes the observation that NaN3, a potent inhibitor of heme proteins such as MPO (31) , blocks cytotoxicity and PAHA production, and that the copresence of the H202 hydrolyzing enzyme catalase eliminates the capacity of activated neutrophils to metabolize procainamide to a cytotoxic product. These conclusions are also supported by the cell free system in which activated neutrophils were replaced by the combination of MPO and either H202 or an H202-generating enzyme (XO). Procainamide oxidation to PAHA in the absence of neutrophils occurred at MPO and 0G-generating activities similar to those observed when neutrophils were activated with opsonized zymosan. In the cell-free studies H202 was derived from G2, a product of xanthine oxidase action on hypoxanthine in contrast to activated neutrophils in which H202 is derived from O°released during the respiratory burst. The necessity for a functioning respiratory burst in neutrophil-mediated metabolism of procainamide is based on the observation that neutrophils from patients with CGD with little or no capacity to produce O2 were incapable of generating PAHA by biochemical and cytotoxicity criteria. Finally, the inability of physiological concentrations of NaOCl and the full capacity of chloride-free media to oxidize procainamide indicate that OCl-is not involved in procainamide oxidation to PAHA by neutrophils. Thus a number of independent lines of investigation provide consistent support for the scheme shown in Fig. 5 .
In general there was a good agreement between procainamide-related cytotoxicity and PAHA generation under the optimum conditions for each system. However, substantial quantitative discrepancies between these assays were observed under some conditions such as low catalase concentration, during PMA-mediated activation and at high neutrophil concentration. In these cases > 1 gM PAHA was detected but procainamide cytotoxicity was 22% with PMA, 11% with catalase and < 5% at > 2 X 106 neutrophils/ml. These discrepancies appear unrelated to the shorter incubation period for the HPLC studies (30 min) compared to the overnight incubation for the cytotoxicity assay, because generation of cytotoxic procainamide metabolites was complete by 1 h exposure of target cells to procainamide in the presence of activated neutrophils. However, previous studies demonstrated that PAHA was not directly cytotoxic but required further oxidation to the nitroso derivative, and ascorbic acid (which was present in the HPLC analyses of neutrophil metabolites) prevents such an oxidative reaction (13) (Table V) . In the absence of ascorbic acid putative nitroso-PA was detected in the cell-free but not in the neutrophil system, perhaps due to formation of covalent bonds with components of the neutrophils themselves. This would suggest that the discordance between procainamide cytotoxicity and PAHA generation may be due to inefficient oxidation of PAHA to nitroso-PA. Neutrophils contain 0.5 mM ascorbic acid (32) which could be a candidate for the putative factor protecting target cells at high neutrophil concentrations, by blocking oxidation of PAHA to nitroso-PA. However, dilution effects and incomplete neutrophil cytolysis would seem to argue against such a role for neutrophil ascorbic acid, although it may be a contributing factor. A more likely candidate for the protective agent is H202, high concentrations of which may oxidize PAHA to noncytotoxic products such as nitro-PA or azoxy-procainamide (16). This would explain the discordance between PAHA generation and marginal cytotoxicity when neutrophils were activated with PMA or with opsonized zymosan at high neutrophil concentrations, since both conditions are associated with high Q2 and, therefore, H202 production. The nonenzymatic oxidation of PAHA by H202 is supported by the data in Table V , demonstrating nitro-and more than five times as much nitroso-PA formation when an initially high H202 concentration was present (30 ,uM) , compared to an enzymatically generated H202 source. Thus, a multilevel role for H202 during MPO-mediated cooxidation of procainamide is proposed, in serving as the primary substrate for MPO, facilitating oxidation of PAHA to cytotoxic nitroso-PA, and at high concentrations inactivating PAHA by transformation to higher state oxidation products. Further studies will be needed to test these concepts.
The present studies establish the capacity of neutrophils to metabolize procainamide to reactive forms. Cytotoxicity of these metabolites per se may be important in the leukopenia occasionally observed in procainamide-induced lupus (33) and/or in release of nuclear debris from killed cells, which may then become immunogenic. However, subtoxic concentrations of procainamide metabolites may also be capable of altering lymphocyte function, as suggested by recent studies demonstrating hyperactivation of mitogen-treated lymphocytes exposed to sublethal concentrations of PAHA or nitroso-PA (34) . It is also possible that PAHA may effect catabolism or processing of autoantigens, thereby increasing their localized concentration or possibly creating abnormal forms capable of initiating autoantibody production. Relevant to this possibility is the observation that patients with procainamideinduced lupus invariably develop IgG antibodies to a subnucleosome derivative of chromatin, the H2A-H2B complex (35) . The present demonstration of neutrophil-mediated metabolism of procainamide provides the precedent for a similar process by other phagocytic cells such as macrophage or by monocytes. Lymphoid compartments containing these cells may generate reactive forms of procainamide which may interfere with control of self-tolerance, leading to development of autoimmunity.
